Sunday, August 10, 2025

Medipharm Labs Delays Q1 Financials, Announces Inventory Impairments

Medipharm Labs (TSX: LABS) this morning announced that it will be delaying its first quarter financial results, with the company giving a blanket statement that it expects to file by the end of June. Furthermore, the company also announced that it will be conducting impairments on inventory among other items as a result of the ongoing pandemic.

With respect to inventory, Medipharm this morning let it be known that the company is expecting to impair anywhere from $10 to $15 million within its first quarter financials. The company blamed the impairment on reduced demand due to the current coronavirus pandemic. Overall, a number of reasons were cited that lead up to the announcement within the news release including:

  • Reduced staff at provincial distributors and private retailers, which the company claims resulted in reduced purchase orders and delivery availability, impacting white label sales.
  • Delays in anticipated expansions of retail channels and slower licensing of cannabis derivative businesses.
  • Producers being slower to implement capabilities to convert bulk extract to finished goods due to operational slowdowns.

These factors were all blamed for oversupply conditions of bulk extract product within the Canadian market, including subsequent lower selling price points and volumes, which ultimately resulted in these writedowns occurring. The company provided no guidance on revenue figures.

Medipharm Labs reported product inventories of $51.5 million as of December 31, 2019. The company last traded at $1.54 on the TSX.


Information for this briefing was found via Sedar and MediPharm Labs. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

New Found Gold: The Queensway PEA

Newmont Q2 Earnings: Setting The Tone For This Earnings Cycle

Highest Grade Antimony Mine in the World!? | James Atkinson – Antimony Resources

Recommended

Nova Scotia Bans Forest Access to Prevent Wildfires

Cardiol Therapeutics Releases Positive Topline Results From Phase II Clinical Trial

Related News

Medipharm Labs Receives Price Target Reduction From Canaccord To $1.75

Yesterday, On November 16th, Medipharm Labs (TSX: LABS) reported their third quarter financial results. Reported...

Tuesday, November 17, 2020, 03:37:00 PM

Champignon Brands Appoints Medipharm Labs CEO Pat McCutcheon to Board

This morning Champignon Brands Inc. (CSE: SHRM) announced the appointment of Pat McCutcheon to its...

Wednesday, May 6, 2020, 09:18:25 AM

Medipharm Labs Sees Revenues Crater 65.8% Quarter Over Quarter

Medipharm Labs (TSX: LABS) has seen its revenues absolutely implode in a single quarter. The...

Thursday, June 18, 2020, 08:35:37 AM

Medipharm Labs Expands Facility Threefold, Introduces New Automated Processes

Medipharm Labs (TSX: LABS) has received Health Canada licensing for its newly expanded production facility...

Monday, December 30, 2019, 08:25:07 AM

Canaccord Genuity Raises Medipharm Labs’ Price Target To C$2.50

On Monday Medipharm Labs (TSX: LABS) announced an exclusive medical cannabis partnership with the European...

Tuesday, October 6, 2020, 01:29:18 PM